Anthem Biosciences Limited (formerly known as Anthem Biosciences Private Limited) announced the outcome of its Board Meeting held on February 05, 2026. The Board approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025, along with the Limited Review Report from the Statutory Auditors. The financial results, reviewed by the Audit Committee, showed a total income of ₹4,564.98 crore for the standalone entity in Q3 FY26, with a profit after tax of ₹1,121.25 crore. For the nine-month period ended December 31, 2025, standalone total income was ₹16,282.61 crore, and profit after tax was ₹4,588.98 crore. On a consolidated basis, total income for Q3 FY26 was ₹4,566.83 crore, and profit after tax was ₹928.17 crore. For the nine-month period ended December 31, 2025, consolidated total income stood at ₹16,179.60 crore, with a profit after tax of ₹4,020.34 crore. Additionally, the Board approved the allotment of 1,03,800 Equity Shares of face value of ₹2 each to eligible employees under the Anthem Employee Stock Option Plan 2024. This allotment increases the company's paid-up equity share capital to ₹1,12,34,27,702. The announcement also noted an exceptional item of ₹249.84 crore in standalone results and ₹253.71 crore in consolidated results, related to the assessment of new Labour Codes notified by the Government of India.
